Abstract
Phase I clinical trials have shown that pure human butyrylcholinesterase (BChE) is safe when administered to humans. A potential therapeutic use of BChE is for prevention of nerve agent toxicity. A recombinant mutant of BChE that rapidly inactivates cocaine is being developed as a treatment to help recovering cocaine addicts avoid relapse into drug taking. These clinical applications rely on knowledge of the structure, stability, and properties of BChE, information that is reviewed here. Gene therapy with a vector that sustains expression for a year from a single injection is a promising method for delivering therapeutic quantities of BChE.
Original language | English (US) |
---|---|
Pages (from-to) | 34-46 |
Number of pages | 13 |
Journal | Pharmacology and Therapeutics |
Volume | 148 |
DOIs | |
State | Published - Apr 2015 |
Keywords
- Butyrylcholinesterase
- Clinical use
- Cocaine
- Genetic variants
- Nerve agent
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)